0001415889-24-022361.txt : 20240827
0001415889-24-022361.hdr.sgml : 20240827
20240827194447
ACCESSION NUMBER: 0001415889-24-022361
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240827
FILED AS OF DATE: 20240827
DATE AS OF CHANGE: 20240827
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Leheny A. Rachel
CENTRAL INDEX KEY: 0001484729
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39538
FILM NUMBER: 241250651
MAIL ADDRESS:
STREET 1: C/O ANTHERA PHARMACEUTICALS, INC.
STREET 2: 25801 INDUSTRIAL BOULEVARD, SUITE B
CITY: HAYWARD
STATE: CA
ZIP: 94545
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CalciMedica, Inc.
CENTRAL INDEX KEY: 0001534133
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 452120079
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: 858-952-5500
MAIL ADDRESS:
STREET 1: 505 COAST BOULEVARD SOUTH
STREET 2: SUITE 307
CITY: LA JOLLA
STATE: CA
ZIP: 92037
FORMER COMPANY:
FORMER CONFORMED NAME: CalciMedica, Inc. /DE/
DATE OF NAME CHANGE: 20230322
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG VISION, INC.
DATE OF NAME CHANGE: 20170717
FORMER COMPANY:
FORMER CONFORMED NAME: GRAYBUG, Inc.
DATE OF NAME CHANGE: 20150303
4
1
form4-08272024_110843.xml
X0508
4
2024-08-27
0001534133
CalciMedica, Inc.
CALC
0001484729
Leheny A. Rachel
C/O CALCIMEDICA, INC.
505 COAST BLVD. S. #307
LA JOLLA
CA
92037
true
true
true
false
CHIEF EXECUTIVE OFFICER
0
Common Stock
2024-08-27
4
P
0
1000
4.1898
A
110926
D
Common Stock
1000
I
By Spouse
Common Stock
356989
I
By Valence Investments SPV IV, LLC
Common Stock
66228
I
By Valence Investments SPV V, LLC
Common Stock
316109
I
By Valence Investments SPV VI, LLC
The weighted average purchase price for the transaction reported was $4.1898, and the range of prices were between $4.20 and $4.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
/s/ John Dunn, Attorney-in-Fact
2024-08-27